ID

36650

Beskrivning

A Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least Two Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT02409368

Länk

https://clinicaltrials.gov/show/NCT02409368

Nyckelord

Versioner (2)
  1. 2019-05-28 2019-05-28 -
  2. 2019-05-28 2019-05-28 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

28 maj 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Non-Small Cell Lung Cancer NCT02409368

Engelsk

Eligibility Non-Small Cell Lung Cancer NCT02409368

1 Formulär  
Criteria
Beskrivning

Criteria

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
easter cooperative oncology group (ecog) status: performance status (ps) 0-1 & ps 2
Beskrivning

ECOG performance status

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
subjects with histologically or cytologically-documented sqnsclc
Beskrivning

Squamous non-small cell lung cancer

Datatyp

boolean

Alias
UMLS CUI [1]
C4509816
subjects must have experienced disease progression or recurrence during or after both a platinum doublet-based chemotherapy regimen and at least 1 additional systemic therapy
Beskrivning

Disease Progression | Recurrence | Status post Chemotherapy Platinum-Based Double | Status post Systemic therapy Quantity

Datatyp

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2]
C0034897
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C0392920
UMLS CUI [3,3]
C1514162
UMLS CUI [3,4]
C0205173
UMLS CUI [4,1]
C0231290
UMLS CUI [4,2]
C1515119
UMLS CUI [4,3]
C1265611
subjects must have evaluable disease by ct or mri per response evaluation criteria in solid tumors (recist 1.1) criteria
Beskrivning

Evaluable Disease CT | Evaluable Disease MRI

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1516986
UMLS CUI [1,2]
C0040405
UMLS CUI [2,1]
C1516986
UMLS CUI [2,2]
C0024485
subjects with treated or asymptomatic cns metastases
Beskrivning

CNS metastases Treated | CNS metastases Asymptomatic

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C1522326
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231221
prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration
Beskrivning

Palliative course of radiotherapy Completed

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0475092
UMLS CUI [1,2]
C0205197
males and females, ages 18 or older
Beskrivning

Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with untreated, symptomatic cns metastases
Beskrivning

CNS metastases Untreated | CNS metastases Symptomatic

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231220
subjects with carcinomatous meningitis
Beskrivning

Meningeal Carcinomatosis

Datatyp

boolean

Alias
UMLS CUI [1]
C0220654
subjects with active, known or suspected autoimmune disease
Beskrivning

Autoimmune Disease | Autoimmune Disease Suspected

Datatyp

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2,1]
C0004364
UMLS CUI [2,2]
C0750491
subjects who received prior therapy with anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody (including ipilimumab or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized bms clinical trial for nivolumab or ipilimumab
Beskrivning

Prior Therapy | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | CD137 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody | ipilimumab | Monoclonal Antibodies | Targeted Therapy T cell costimulation | Study Subject Participation Status | nivolumab

Datatyp

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C4289970
UMLS CUI [3]
C4289971
UMLS CUI [4,1]
C1705357
UMLS CUI [4,2]
C0003250
UMLS CUI [5,1]
C0214721
UMLS CUI [5,2]
C0003250
UMLS CUI [6]
C4289973
UMLS CUI [7]
C1367202
UMLS CUI [8]
C0003250
UMLS CUI [9,1]
C2985566
UMLS CUI [9,2]
C1622572
UMLS CUI [10]
C2348568
UMLS CUI [11]
C3657270
Tillbaka till toppen

Similar models

Eligibility Non-Small Cell Lung Cancer NCT02409368

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Item Group
C1512693 (UMLS CUI)
ECOG performance status
Item
easter cooperative oncology group (ecog) status: performance status (ps) 0-1 & ps 2
boolean
C1520224 (UMLS CUI [1])
Squamous non-small cell lung cancer
Item
subjects with histologically or cytologically-documented sqnsclc
boolean
C4509816 (UMLS CUI [1])
Disease Progression | Recurrence | Status post Chemotherapy Platinum-Based Double | Status post Systemic therapy Quantity
Item
subjects must have experienced disease progression or recurrence during or after both a platinum doublet-based chemotherapy regimen and at least 1 additional systemic therapy
boolean
C0242656 (UMLS CUI [1])
C0034897 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C1514162 (UMLS CUI [3,3])
C0205173 (UMLS CUI [3,4])
C0231290 (UMLS CUI [4,1])
C1515119 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
Evaluable Disease CT | Evaluable Disease MRI
Item
subjects must have evaluable disease by ct or mri per response evaluation criteria in solid tumors (recist 1.1) criteria
boolean
C1516986 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
C1516986 (UMLS CUI [2,1])
C0024485 (UMLS CUI [2,2])
CNS metastases Treated | CNS metastases Asymptomatic
Item
subjects with treated or asymptomatic cns metastases
boolean
C0686377 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0231221 (UMLS CUI [2,2])
Palliative course of radiotherapy Completed
Item
prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration
boolean
C0475092 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
Age
Item
males and females, ages 18 or older
boolean
C0001779 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
CNS metastases Untreated | CNS metastases Symptomatic
Item
subjects with untreated, symptomatic cns metastases
boolean
C0686377 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Meningeal Carcinomatosis
Item
subjects with carcinomatous meningitis
boolean
C0220654 (UMLS CUI [1])
Autoimmune Disease | Autoimmune Disease Suspected
Item
subjects with active, known or suspected autoimmune disease
boolean
C0004364 (UMLS CUI [1])
C0004364 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Prior Therapy | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | CD137 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody | ipilimumab | Monoclonal Antibodies | Targeted Therapy T cell costimulation | Study Subject Participation Status | nivolumab
Item
subjects who received prior therapy with anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody (including ipilimumab or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized bms clinical trial for nivolumab or ipilimumab
boolean
C1514463 (UMLS CUI [1])
C4289970 (UMLS CUI [2])
C4289971 (UMLS CUI [3])
C1705357 (UMLS CUI [4,1])
C0003250 (UMLS CUI [4,2])
C0214721 (UMLS CUI [5,1])
C0003250 (UMLS CUI [5,2])
C4289973 (UMLS CUI [6])
C1367202 (UMLS CUI [7])
C0003250 (UMLS CUI [8])
C2985566 (UMLS CUI [9,1])
C1622572 (UMLS CUI [9,2])
C2348568 (UMLS CUI [10])
C3657270 (UMLS CUI [11])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial